Zdrowie i gospodarka · 13/08/2001

FDA Releases Draft Guidance on Biological Product Deviation Reporting for Blood and Plasma Establishments

The FDA has made available a draft document outlining the agency's requirements for reporting deviations in biological products used in blood and plasma establishments, aiming to clarify the process for licensed and unlicensed blood establishments and transfusion services.